Approved consistent with the following terms of clearance: upon completion of the first round of the survey ONDCP will provide OMB with a report of survey findings and achieved response rates at each site; consistent with the limitations of the study design, reporting of survey results will indicate that the survey is a purposive, non-probability sample of sentinel sights that is not representative of the US as a whole or individual states or other areas that were not surveyed; additionally comparisons with prior iterations of the ADAM survey should include a discussion of variability in the data set over time and differences in the coverage areas of the original DOJ survey and the current ONDCP ADAM survey.
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
03/31/2010
36 Months From Approved
5,000
0
0
1,667
0
0
1,320,000
0
0
The Office of National Drug Control PolicyÂs (ONDCPÂs) mission, since its authorization in 1988, has been to establish the NationÂs drug control policy, to set priorities for advancing that policy, and to identify and monitor objective measures of that policyÂs success. The original Arrestee Drug Abuse Monitoring program (ADAM) was a critical source of data for ONDCP in meeting its objectives, and its demise in 2003 left a serious gap in accurate and timely information on trends in drug use.
The first ADAM data collection was instituted in 2000 as a replacement for the Drug Use Forecasting program (DUF), which employed a non-scientific sampling procedure to select primarily felony arrestees in 23 urban areas throughout the country. The year 2000 revision of ADAM instituted a representative sampling strategy among booked male arrestees in an expanded network of 35 sites. The original OMB approval for this collection authorized 100,000 responses and a time burden of 62,500 hours (OMB control # 1121-0137). That authorization expired in 2005.
With ADAM II, ONDCP and its contractor, Abt Associates, Inc., will initiate a new data collection that will replicate the ADAM methodology in order to obtain data comparable to previously established trends. ADAM II will implement two quarters of data collection in ten sentinel ADAM sites to revive monitoring drug trends, with a particular focus on obtaining valid and reliable information on methamphetamine use. Representing minimal adjustments to the previously approved ADAM survey, the ADAM II survey will collect data about drug use, drug and alcohol dependency and treatment, and drug market participation among booked male arrestees within 48 hours of arrest. Data collection will take place across two back-to-back quarters in each of 10 counties from a county-based representative sample of 250 male arrestees per quarter for a total of 500 arrestees annually per site or a total of 5000 arrestees across sites annually. Collection will occur in two cycles at each site to provide estimates for two calendar quarters each year. One year of collection will occur beginning April 1, 2007 and ending March 31, 2008. If additional data collection periods are optioned by ONDCP, subsequent cycles of back-to-back data collection will occur beginning April 1, 2008. Participation is voluntary and confidential, and the procedures will include a personal interview (lasting approximately 20 minutes) and collection of a urine specimen. Though a convenience sample of female and juvenile arrestees was a part of the previous ADAM program, those groups will be excluded from this effort for the purposes of economy.
This ICR requests approval for a data collection using a survey instrument (w/minimal update changes)of a previously approved collection (OMB Control # 1121-0137) for which approval has expired. The original OMB approval authorized 100,000 responses and a time burden of 62,500 hours. That authorization expired in 2005. This ICR requests significantly less responses and time burden than the original effort (5,000 responses and 1,667 hours per year).
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
Appl Appr NIH Cert of Conf.pdf
Abstract-ADAM II OMB Final.doc
Arrestee Drug Abuse Monitoring (ADAM II)